Cost Insights: Breaking Down Amgen Inc. and ADMA Biologics, Inc.'s Expenses

Amgen vs. ADMA: A Decade of Cost Dynamics

__timestampADMA Biologics, Inc.Amgen Inc.
Wednesday, January 1, 201437423674422000000
Thursday, January 1, 201543114614227000000
Friday, January 1, 201663607614162000000
Sunday, January 1, 2017291643214069000000
Monday, January 1, 2018421946354101000000
Tuesday, January 1, 2019395042384356000000
Wednesday, January 1, 2020612914266159000000
Friday, January 1, 2021797693416454000000
Saturday, January 1, 20221188145356406000000
Sunday, January 1, 20231692730008415000000
Monday, January 1, 202412858000000
Loading chart...

Unleashing insights

Cost Insights: Amgen Inc. vs. ADMA Biologics, Inc.

In the ever-evolving landscape of biotechnology, understanding cost structures is crucial. This analysis delves into the cost of revenue for two industry players: Amgen Inc. and ADMA Biologics, Inc., from 2014 to 2023. Over this period, Amgen's cost of revenue consistently dwarfed that of ADMA, reflecting its larger scale and market presence. In 2023, Amgen's expenses surged to 8.4 billion, marking a 90% increase from 2014. Meanwhile, ADMA's costs grew exponentially, rising by over 4,400% to reach 169 million in 2023. This stark contrast highlights the differing growth trajectories and operational scales of these companies. While Amgen's costs reflect its established market dominance, ADMA's rapid increase underscores its aggressive expansion strategy. These insights provide a window into the financial dynamics shaping the biotech sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025